印度制药业在农村保健、税收优惠和减税方面寻求增加预算。 Indian pharmaceutical industry seeks budget increase for rural healthcare, tax benefits, and duty cuts.

印度制药和保健行业正在争取在即将到来的2025年联邦预算中将保健预算拨款增加2.5%-3%,重点是改善农村和半城市地区的基础设施。 The Indian pharmaceutical and healthcare industry is pushing for a 2.5-3% increase in healthcare budget allocation in the upcoming Union Budget 2025, focusing on improving infrastructure in rural and semi-urban areas. 关键要求包括恢复研究和开发的税收优惠,降低医疗保险费的GST税率,以及降低救生药品的关税。 Key asks include reinstating tax benefits for research and development, lowering GST rates on health insurance premiums, and reducing customs duties on life-saving drugs. 这些改革可以提高印度作为全球制药枢纽的地位,因为印度的制药业在24财政年度增长9%,达到540亿美元。 These reforms could boost India's position as a global pharmaceutical hub, following a 9% growth in the sector to USD 54 billion in FY24.